Safety and Immunogenicity of Adenovirus and Poxvirus Vectored Vaccines against a Mycobacterium Avium Complex Subspecies

por Folegatti, Pedro M., Flaxman, Amy, Jenkin, Daniel, Makinson, Rebecca, Kingham-Page, Lucy, Bellamy, Duncan, Ramos Lopez, Fernando, Sheridan, Jonathan, Poulton, Ian, Aboagye, Jeremy, Tran, Nguyen, Mitton, Celia, Roberts, Rachel, Lawrie, Alison M., Hill, Adrian V. S., Ewer, Katie J., Gilbert, Sarah
Publicado 2021

Safety and immunogenicity of a simian-adenovirus-vectored rabies vaccine: an open-label, non-randomised, dose-escalation, first-in-human, single-centre, phase 1 clinical trial

por Jenkin, Daniel, Ritchie, Adam J, Aboagye, Jeremy, Fedosyuk, Sofiya, Thorley, Luke, Provstgaad-Morys, Samuel, Sanders, Helen, Bellamy, Duncan, Makinson, Rebecca, Xiang, Zhi Quan, Bolam, Emma, Tarrant, Richard, Lopez, Fernando Ramos, Platt, Abigail, Poulton, Ian, Green, Catherine, Ertl, Hildegund C J, Ewer, Katie J, Douglas, Alexander D
Publicado 2022

Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trial

por Bosaeed, Mohammad, Balkhy, Hanan H, Almaziad, Sultan, Aljami, Haya A, Alhatmi, Hind, Alanazi, Hala, Alahmadi, Mashael, Jawhary, Ayah, Alenazi, Mohammed W, Almasoud, Abdulrahman, Alanazi, Rawan, Bittaye, Mustapha, Aboagye, Jeremy, Albaalharith, Nahla, Batawi, Sarah, Folegatti, Pedro, Ramos Lopez, Fernando, Ewer, Katie, Almoaikel, Khalid, Aljeraisy, Majed, Alothman, Adel, Gilbert, Sarah C, Khalaf Alharbi, Naif
Publicado 2022

Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial

por Madhavan, Meera, Ritchie, Adam J., Aboagye, Jeremy, Jenkin, Daniel, Provstgaad-Morys, Samuel, Tarbet, Iona, Woods, Danielle, Davies, Sophie, Baker, Megan, Platt, Abigail, Flaxman, Amy, Smith, Holly, Belij-Rammerstorfer, Sandra, Wilkins, Deidre, Kelly, Elizabeth J., Villafana, Tonya, Green, Justin A., Poulton, Ian, Lambe, Teresa, Hill, Adrian V.S., Ewer, Katie J., Douglas, Alexander D.
Publicado 2022

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)

por Flaxman, Amy, Marchevsky, Natalie G, Jenkin, Daniel, Aboagye, Jeremy, Aley, Parvinder K, Angus, Brian, Belij-Rammerstorfer, Sandra, Bibi, Sagida, Bittaye, Mustapha, Cappuccini, Federica, Cicconi, Paola, Clutterbuck, Elizabeth A, Davies, Sophie, Dejnirattisai, Wanwisa, Dold, Christina, Ewer, Katie J, Folegatti, Pedro M, Fowler, Jamie, Hill, Adrian V S, Kerridge, Simon, Minassian, Angela M, Mongkolsapaya, Juthathip, Mujadidi, Yama F, Plested, Emma, Ramasamy, Maheshi N, Robinson, Hannah, Sanders, Helen, Sheehan, Emma, Smith, Holly, Snape, Matthew D, Song, Rinn, Woods, Danielle, Screaton, Gavin, Gilbert, Sarah C, Voysey, Merryn, Pollard, Andrew J, Lambe, Teresa
Publicado 2021

Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials

por Voysey, Merryn, Flaxman, Amy, Aboagye, Jeremy, Aley, Parvinder K, Belij-Rammerstorfer, Sandra, Bibi, Sagida, Bittaye, Mustapha, Cappuccini, Federica, Charlton, Sue, Clutterbuck, Elizabeth A, Davies, Sophie, Dold, Christina, Edwards, Nick J, Ewer, Katie J, Faust, Saul N, Folegatti, Pedro M, Fowler, Jamie, Gilbride, Ciaran, Gilbert, Sarah C, Godfrey, Leila, Hallis, Bassam, Humphries, Holly E, Jenkin, Daniel, Kerridge, Simon, Mujadidi, Yama F, Plested, Emma, Ramasamy, Maheshi N, Robinson, Hannah, Sanders, Helen, Snape, Matthew D, Song, Rinn, Thomas, Kelly M, Ulaszewska, Marta, Woods, Danielle, Wright, Daniel, Pollard, Andrew J, Lambe, Teresa
Publicado 2023